PT -期刊文章盟詹姆斯Brenton盟艾玛Woolbright AU -苏分盟仁Koshiya盟Myla高盛TI -儿科学科女士健康对照组相比减少了行走能力(4818)DP - 2020年4月14日TA -神经病学PG - 4818 VI - 94 IP - 15补充4099 - //www.ez-admanager.com/content/94/15_Supplement/4818.short 4100 - http://n.neurology.o首页rg/content/94/15_Supplement/4818.full所以Neurology2020 4月14日;94 AB -目的:评估的效用6分钟步行试验歧视行走能力的儿童相比,非MS女士控制。背景:小儿女士比健康的同龄人表现出低强度到高强度的体育运动,以连续个加速器。当个加速器主要决定步行行为,有一个明显缺乏知识在女士的孩子步行能力6分钟步行(6 mw)是一个时间步行测试评估行走易疲劳性和功能性行走能力。应用作为一种重要的测量结果在成人女士,这个测试在儿科人口女士的值是未知的。设计/方法:25儿科女士和50名健康受试者招募的控制。所有儿科学科女士遇到了2010年和2017年麦当劳标准研究人口统计学和人体测量信息收集女士访问包括年龄,性别,种族,体重/身高,腰围,吸烟史。所有受试者完成了6 mw评估使用一个标准化的协议。女士的研究对象接受扩大残疾状态量表(eds)评估。结果:儿科女士受试者的平均年龄17岁(范围:11到18门年)平均疾病持续时间2年。中位数eds女士科目分数为1.5。 A greater proportion of MS subjects were overweight/obese compared to controls (60% versus 33%). Pediatric MS subjects walked a significantly shorter distance in 6 minutes (6MW) compared to controls (1868 +/− 252 versus 2061 +/− 254 feet; p=0.004). In regression modeling, both MS disease and higher body mass index (BMI) influence performance on the 6MW, even after adjusting for level of neurologic disability (determined by EDSS).Conclusions: Pediatric MS subjects exhibit a slower performance on 6MW compared to non-MS peers, suggesting a lowered functional walking capacity independent of MS disability. Additionally, elevated BMI impacts 6MW performance, with slowest performance noted in those children who are obese and living with MS.Disclosure: Dr. Brenton has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Novartis.Dr. Woolbright has nothing to disclose. Dr. Min has nothing to disclose. Dr. Koshiya has nothing to disclose. Dr. Goldman has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with EMD Serono, Genzyme, Novartis Pharmaceuticals, Teva Neuroscience, RxMx, and Celgene. Dr. Goldman has received research support from MedDay, Novartis Pharmaceuticals, PCORI, and NMSS.